K
v
ire
.com
←
Back
Night
Docs
Library
Review
…
Author
Georgina V. Long
also known as A Menzies, G Long, G V Long
The University of Sydney · Roche (Switzerland) · Scripps Research Institute · Brigham and Women's Hospital
About this author
Works
1,819
Cited by
174,358
h-index
170
i10
644
ORCID ↗
Top papers
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González, et al.
·
2015
·
New England Journal of Medicine
↗ 8,092
OA
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long, et al.
·
2015
·
New England Journal of Medicine
↗ 5,806
OA
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González, et al.
·
2017
·
New England Journal of Medicine
↗ 5,360
OA
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Caroline Robert, Georgina V. Long, Benjamin Brady, et al.
·
2014
·
New England Journal of Medicine
↗ 5,328
OA
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
James Larkin, Vanna Chiarion‐Sileni, René González, et al.
·
2019
·
New England Journal of Medicine
↗ 3,665
OA
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty, J. Infante, Adil Daud, et al.
·
2012
·
New England Journal of Medicine
↗ 2,792
OA
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Caroline Robert, Bogusława Karaszewska, Jacob Schachter, et al.
·
2014
·
New England Journal of Medicine
↗ 2,638
OA
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
Daniel Wang, Joe‐Elie Salem, Justine V. Cohen, et al.
·
2018
·
JAMA Oncology
↗ 2,548
OA
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
Jeffrey E. Gershenwald, Richard A. Scolyer, Kenneth R. Hess, et al.
·
2017
·
CA A Cancer Journal for Clinicians
↗ 2,264
OA
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, et al.
·
2017
·
New England Journal of Medicine
↗ 2,187
OA
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, et al.
·
2014
·
New England Journal of Medicine
↗ 1,854
OA
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, et al.
·
2018
·
New England Journal of Medicine
↗ 1,830
OA